Ann: Investor Presentation, page-7

First 7 Last

Share
Profile

Follow
Surandy70

11,413 Posts.

1949

06/06/22

23:02

Post #: 61854404
Share

Originally posted by adent: ↑

right, so the SP will drop to 19 cents or maybe even 15 cents. Mosts CRs seem to have the effect of dropping the SP to the CR price.

The options expire 5 months after they are issued. This seems very short.
Likelyhood of the price rising from 19 cents to above 30 cents in 5 months?

To exercise the options a holder needs to have a minimum of 5000. If a holder has less than 12750 shares, then even if they take up the full offer, they will not receive enough options to be exercised. Only choice would be to sell the options before Nov, or the options evaporate.

The purpose of the CR is to provide 6 months of funding (aka till end of CY 2022).

As LDX have negative cashflow. The 2023 activities rely entirely on revenue from the options at 30 cents per option. I wonder how many shares are currently with holders that have less that 12750 shares, and therefore those options will evaporate.

LDX are hinging the entire strategy post Xmas on the share price getting above 30 cents by Nov.
Planet Innovation are all in, with a $6 million commitment. Nice.
Directors are all in. Also nice.
The compensation for the new CEO doesn't seem execessive, compared to some more speculative stocks I've seen. But is still way to high in terms of compenstation with options. IMO
If the share price cannot get above 30 cents before Nov 2022, then I assume LDX tries to rattle the can again.

Well, its all a gamble after all.

Expand

The options, if holding less than 5,000, don't evaporate. They just have to be exercised in one go, ie you cannot exercise half and hold onto half.

If you hold sufficient shares to take up say 6,000 new entitlement shares with 6,000 attached options then if looking to exercise the options you can exercise them all or if you want to hold onto some then you can exercise a minimum of 5,000.

LDX Price at posting: 25.5¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

3DA

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

GDM

Banshee's historic trenches prove rich in antimony and gold for GDM

IRX

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

There are more pages in this discussion • 18 more messages in this thread...

First 7 Last

Add LDX (ASX) to my watchlist

(20min delay)
Last 3.0¢		Change 0.000(0.00%)		Mkt cap ! $22.37M

Open	High	Low	Value	Volume
3.0¢	3.2¢	3.0¢	$62.84K	2.040M

Buyers (Bids)

No.	Vol.	Price($)
2	61662	3.0¢

Sellers (Offers)

Price($)	Vol.	No.
3.1¢	480827	6

View Market Depth

No.	Vol.	Price($)
2	61662	0.030
6	368474	0.029
4	400000	0.028
2	274074	0.027
2	378500	0.026

Price($)	Vol.	No.
0.031	480827	6
0.032	367841	5
0.033	870322	5
0.035	83001	1
0.038	250359	3

Last trade - 13.41pm 15/11/2024 (20 minute delay)

LDX (ASX) Chart

Ann: Investor Presentation, page-7

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-7

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Banshee's historic trenches prove rich in antimony and gold for GDM

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News